Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087542 · ClinicalTrials.gov registry record · Phase 2
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00087542 is a Phase 2 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00087542, a Phase 2 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's disease patients taking multiple anti-parkinsonian medications.
Interventions
- DRUG ACP-103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087542
The ClinicalTrials.gov registry entry for NCT00087542 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACP-103 is the first listed.
NCT00087542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087542 about?
NCT00087542 is a clinical study titled "Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug". The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate psychosis in patients with Parkins...
What is the current status of trial NCT00087542?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-03. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00087542?
The interventions under investigation include: ACP-103 (DRUG).
Who is sponsoring clinical trial NCT00087542?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.